Financial Performance - As of December 31, 2025, the company reported a cash balance of $393.3 million[12] - For the fiscal year ending December 31, 2025, the company generated revenue of $56.2 million, including $25.0 million from drug discovery, $23.9 million from pipeline development, $4.9 million from software solutions, and $2.5 million from other discoveries[12] - The net loss for the fiscal year ending December 31, 2025, increased by $335.2 million to $352.3 million, attributed to decreased revenue and fair value losses on financial liabilities[12] - Adjusted losses (non-IFRS measure) increased by $21.2 million to $43.8 million, primarily due to a decline in revenue, partially offset by reduced R&D expenses[12] - Total revenue decreased by 34.5% from $85.8 million in 2024 to $56.2 million in 2025, primarily due to a decline in pipeline development revenue[46] - Gross profit fell by 40.9% from $77.6 million in 2024 to $45.8 million in 2025, attributed to changes in revenue structure and increased costs[48] - The company reported a net loss of $352.316 million for the year ended December 31, 2025, compared to a net loss of $17.096 million in 2024, marking a significant increase in losses[82] - Basic and diluted loss per share for 2025 was $(4.48), compared to $(0.24) in 2024, reflecting a substantial decline in financial performance[103] Research and Development - Research and development expenses for the fiscal year ending December 31, 2025, were $81.4 million, a decrease of $10.5 million compared to the previous year, primarily due to reduced third-party CRO costs[12] - The company expanded its product pipeline by adding six AI-enabled PCCs, bringing the total to 28, enhancing future licensing potential[9] - The company is advancing multiple clinical trials, including ISM001-055 for idiopathic pulmonary fibrosis and ISM5411 for inflammatory bowel disease, with promising results expected in 2025[10] - The company has generated over 20 clinical or IND-stage assets through its Pharma.AI platform, with a total contract value of up to $2.1748 billion, including $130.3 million in upfront payments and $2.0445 billion in milestone payments[13] - The average time for candidate drug development from target discovery to PCC confirmation is 12 to 18 months, significantly shorter than the traditional average of 4.5 years[14] - ISM001-055 (Rentosertib) received breakthrough therapy designation for IPF and showed a significant average improvement in FVC of +98.4 mL compared to a decline of -20.3 mL in the placebo group[28] - The company’s pipeline is entirely self-developed, with no licensing of targets or compounds from other pharmaceutical companies[27] Partnerships and Collaborations - The company established high-value partnerships with leading multinational pharmaceutical companies, resulting in new business development agreements totaling over $1.3 billion[11] - The company collaborates with 13 of the top 20 global pharmaceutical companies to accelerate drug discovery, with transaction structures including upfront payments and milestone payments[37] - A major licensing agreement was established with TaiJing Biotechnology for the exclusive rights to develop and commercialize ISM4808 in Greater China, with total transaction value reaching tens of millions of dollars[38] - The collaboration pipeline saw exceptional growth, including a partnership with Eli Lilly that allows the company to receive over $100 million in payments, and a multi-year oncology collaboration with Servier valued at up to $888 million[39] AI and Technology Development - The company launched significant upgrades to its Pharma.AI platform, enhancing capabilities in drug discovery and development[5] - The AI platform PandaOmics achieved a retrieval rate of 71.6% for known clinical targets, outperforming public platforms by two to three times[19] - TargetPro's predicted new targets show 95.7% structural availability, 86.5% drugability, and 46% repurposing potential, all exceeding competitive systems[19] - The Alchemistry 2.0 engine has improved speed by two to four times while achieving industry-level accuracy in relative binding free energy predictions[20] - The Pharma.AI platform continues to enhance its capabilities with upgrades to Biology42, Chemistry42, and Science42, aiming for a vision of pharmaceutical superintelligence[18] Financial Position and Assets - As of December 31, 2025, the company recorded net assets of $452.0 million, a significant change attributed to the conversion of preferred shares to common stock and increased cash reserves[61] - Bank balances and cash increased by $267.4 million from $125.9 million in 2024 to $393.3 million in 2025, primarily due to the completion of a global offering in December 2025[66] - Total assets as of December 31, 2025, were $474.278 million, compared to $133.409 million in 2024, indicating a significant increase of about 254%[83] - Trade and other receivables increased from $7.5 million as of December 31, 2024, to $27.0 million as of December 31, 2025, primarily due to recognized but unpaid revenue[62] - Trade and other payables rose from $28.0 million as of December 31, 2024, to $29.7 million as of December 31, 2025, mainly due to increased listing expenses[63] Future Outlook and Strategy - The company plans to expand its strategic collaborations beyond the pharmaceutical sector to leverage the Pharma.AI platform's potential across various industries, including advanced materials and agriculture[43] - The company plans to allocate approximately 48% of net proceeds from the global offering, totaling HK$1,128.14 million, for further clinical research and development of key pipeline candidates over the next three to four years[80] - The company anticipates a revenue guidance of $70 million for the next fiscal year, representing a 50% year-over-year growth[136] - The company’s strategy for 2026 focuses on business development, clinical execution, and commercialization of its AI platform[120] Regulatory and Compliance - The company emphasizes the potential of its AI-driven development methods to provide clinical evidence of efficacy[28] - The IND submissions are made to regulatory agencies such as the FDA and the National Medical Products Administration in China[27] - The company has a tax rate of 16.5% applicable to its operations in Hong Kong[101] - The company has been enjoying a 200% super deduction on eligible R&D expenses for the years ended December 31, 2025, and 2024[101] Shareholder Information - The board of directors has decided not to declare any final dividend for the year ending December 31, 2025[130] - The company did not declare or pay any dividends during the year[104] - The company will suspend the registration of share transfers from May 28, 2026, to June 2, 2026, to determine shareholder voting rights for the annual general meeting[124]
英矽智能(03696) - 2025 - 年度业绩